Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890147119> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2890147119 endingPage "7027" @default.
- W2890147119 startingPage "7027" @default.
- W2890147119 abstract "7027 Background: Outcomes are poor for older patients with AML and MDS who progress on HMAs. Blocking the CXCL12/CXCR4 axis may be therapeutic as this is essential for retention of malignant stem cells in the bone marrow (BM), where they may be protected from the genotoxic stresses of chemotherapy. CX-01 is a low molecular weight heparin derivative with minimal anticoagulant activity that disrupts the CXCL12/ CXCR4 axis, and neutralizes the activity of PF4, a negative regulator of megakaryopoiesis. We hypothesized that CX-01 would re-sensitize patients with HMA-refractory AML and MDS to AZA and mitigate thrombocytopenia. Methods: Patients with HMA-refractory INT-1 or greater MDS and AML received 7 day continuous infusion of CX-01 with 7 day AZA 75 mg/m2 in 28 day cycles. The primary objective was to assess the overall response rate (ORR). Results: To date, 20 patients were treated and 12 are evaluable for response with a BM biopsy after C2. The median age was 74 years. 9 patients had secondary AML, 7 had MDS INT-1, 2 had MDS INT-2, and 2 had de novo AML. 10 patients had poor risk cytogenetics and/or p53 mutations. Baseline BM showed a median 16% blasts. Patients were heavily pretreated, receiving a median of 6 cycles of prior HMA cycles (range 4-20) with 10 patients receiving > 1 prior line of therapy. Patients received a median of 2 cycles of CX-01 with AZA (range 0-5). Of the 12 evaluable patients, there was 1 complete response (CR), 3 marrow CRs (with incomplete count recovery), 7 stable disease, and 1 progressive disease for an ORR of 33%. There was no significant difference in baseline characteristics of responders and the rest of the cohort. 3 of 4 responders had hematologic improvement, 2 with normalization of platelet counts. Median duration of response is 212+ days, with 2 patients disease-free at 192 and 233 days, and all four responding patients still alive. CX-01 was well tolerated, with all severe AEs thought unlikely to be related to CX-01. Conclusions: CX-01 and AZA appears to have an encouraging response rate in HMA-refractory AML/MDS. Treatment was feasible with no instances of study related severe AEs. This trial is ongoing to evaluate the ORR and OS of all patients treated. Clinical trial information: NCT02995655." @default.
- W2890147119 created "2018-09-27" @default.
- W2890147119 creator A5003966906 @default.
- W2890147119 creator A5017335587 @default.
- W2890147119 creator A5027659475 @default.
- W2890147119 creator A5030586623 @default.
- W2890147119 creator A5041735776 @default.
- W2890147119 creator A5059470814 @default.
- W2890147119 creator A5061484901 @default.
- W2890147119 creator A5065066309 @default.
- W2890147119 date "2018-05-20" @default.
- W2890147119 modified "2023-10-16" @default.
- W2890147119 title "CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS." @default.
- W2890147119 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.7027" @default.
- W2890147119 hasPublicationYear "2018" @default.
- W2890147119 type Work @default.
- W2890147119 sameAs 2890147119 @default.
- W2890147119 citedByCount "3" @default.
- W2890147119 countsByYear W28901471192020 @default.
- W2890147119 countsByYear W28901471192021 @default.
- W2890147119 crossrefType "journal-article" @default.
- W2890147119 hasAuthorship W2890147119A5003966906 @default.
- W2890147119 hasAuthorship W2890147119A5017335587 @default.
- W2890147119 hasAuthorship W2890147119A5027659475 @default.
- W2890147119 hasAuthorship W2890147119A5030586623 @default.
- W2890147119 hasAuthorship W2890147119A5041735776 @default.
- W2890147119 hasAuthorship W2890147119A5059470814 @default.
- W2890147119 hasAuthorship W2890147119A5061484901 @default.
- W2890147119 hasAuthorship W2890147119A5065066309 @default.
- W2890147119 hasConcept C104317684 @default.
- W2890147119 hasConcept C121332964 @default.
- W2890147119 hasConcept C126322002 @default.
- W2890147119 hasConcept C141071460 @default.
- W2890147119 hasConcept C142424586 @default.
- W2890147119 hasConcept C143998085 @default.
- W2890147119 hasConcept C150194340 @default.
- W2890147119 hasConcept C185592680 @default.
- W2890147119 hasConcept C190727270 @default.
- W2890147119 hasConcept C2776012956 @default.
- W2890147119 hasConcept C2776239401 @default.
- W2890147119 hasConcept C2776694085 @default.
- W2890147119 hasConcept C2780007613 @default.
- W2890147119 hasConcept C55493867 @default.
- W2890147119 hasConcept C71924100 @default.
- W2890147119 hasConcept C87355193 @default.
- W2890147119 hasConcept C90924648 @default.
- W2890147119 hasConceptScore W2890147119C104317684 @default.
- W2890147119 hasConceptScore W2890147119C121332964 @default.
- W2890147119 hasConceptScore W2890147119C126322002 @default.
- W2890147119 hasConceptScore W2890147119C141071460 @default.
- W2890147119 hasConceptScore W2890147119C142424586 @default.
- W2890147119 hasConceptScore W2890147119C143998085 @default.
- W2890147119 hasConceptScore W2890147119C150194340 @default.
- W2890147119 hasConceptScore W2890147119C185592680 @default.
- W2890147119 hasConceptScore W2890147119C190727270 @default.
- W2890147119 hasConceptScore W2890147119C2776012956 @default.
- W2890147119 hasConceptScore W2890147119C2776239401 @default.
- W2890147119 hasConceptScore W2890147119C2776694085 @default.
- W2890147119 hasConceptScore W2890147119C2780007613 @default.
- W2890147119 hasConceptScore W2890147119C55493867 @default.
- W2890147119 hasConceptScore W2890147119C71924100 @default.
- W2890147119 hasConceptScore W2890147119C87355193 @default.
- W2890147119 hasConceptScore W2890147119C90924648 @default.
- W2890147119 hasIssue "15_suppl" @default.
- W2890147119 hasLocation W28901471191 @default.
- W2890147119 hasOpenAccess W2890147119 @default.
- W2890147119 hasPrimaryLocation W28901471191 @default.
- W2890147119 hasRelatedWork W1983754555 @default.
- W2890147119 hasRelatedWork W2021963759 @default.
- W2890147119 hasRelatedWork W2048281482 @default.
- W2890147119 hasRelatedWork W2054507167 @default.
- W2890147119 hasRelatedWork W2397845545 @default.
- W2890147119 hasRelatedWork W2409251897 @default.
- W2890147119 hasRelatedWork W2559444916 @default.
- W2890147119 hasRelatedWork W2890308086 @default.
- W2890147119 hasRelatedWork W3110674863 @default.
- W2890147119 hasRelatedWork W3203236595 @default.
- W2890147119 hasVolume "36" @default.
- W2890147119 isParatext "false" @default.
- W2890147119 isRetracted "false" @default.
- W2890147119 magId "2890147119" @default.
- W2890147119 workType "article" @default.